Semin intervent Radiol 2015; 32(04): 349-355
DOI: 10.1055/s-0035-1564706
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Irreversible Electroporation

Govindarajan Narayanan
1   Division of Vascular and Interventional Radiology, Department of Radiology, University of Miami-Miller School of Medicine, Miami, Florida
› Author Affiliations
Further Information

Publication History

Publication Date:
10 November 2015 (online)

Abstract

Irreversible electroporation (IRE) is a predominantly nonthermal ablative technology that uses high-voltage, low-energy DC current pulses to induce cell death. Thermal ablative technologies such as radiofrequency ablation, microwave ablation, and cryoablation have several applications in oncology but have limitations that have been established. IRE has shown promise to overcome some of these limitations. This article reviews the basics of the technology, patient selection, clinical applications, practical pointers, and the published data.

 
  • References

  • 1 Rubinsky B. Irreversible electroporation in medicine. Technol Cancer Res Treat 2007; 6 (4) 255-260
  • 2 Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat 2005; 4 (6) 699-705
  • 3 Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng 2006; 53 (7) 1409-1415
  • 4 Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat 2007; 6 (1) 37-48
  • 5 Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 2010; 255 (2) 426-433
  • 6 Thomson KR, Cheung W, Ellis SJ , et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011; 22 (5) 611-621
  • 7 Kingham TP, Karkar AM, D'Angelica MI , et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 2012; 215 (3) 379-387
  • 8 Silk MT, Wimmer T, Lee KS , et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol 2014; 25 (1) 112-118
  • 9 Narayanan G, Bhatia S, Echenique A, Suthar R, Barbery K, Yrizarry J. Vessel patency post irreversible electroporation. Cardiovasc Intervent Radiol 2014; 37 (6) 1523-1529
  • 10 Scheffer HJ, Nielsen K, van Tilborg AA , et al. Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study. Eur Radiol 2014; 24 (10) 2467-2475
  • 11 Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 2007; 6 (4) 295-300
  • 12 Valerio M, Stricker PD, Ahmed HU , et al. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis 2014; 17 (4) 343-347
  • 13 American Cancer Society. Cancer Facts & Figures 2014. American Cancer Society 2014. Available at: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf . Accessed July 2015
  • 14 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61 (2) 69-90
  • 15 Ghosn M, Kourie HR, El Karak F, Hanna C, Antoun J, Nasr D. Optimum chemotherapy in the management of metastatic pancreatic cancer. World J Gastroenterol 2014; 20 (9) 2352-2357
  • 16 Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg 2010; 97 (2) 220-225
  • 17 Wu Y, Tang Z, Fang H , et al. High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer. J Surg Oncol 2006; 94 (5) 392-395
  • 18 Martin II RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol 2013; 20 (Suppl. 03) S443-S449
  • 19 Narayanan G, Froud T, Suthar R, Barbery K, Yrizarry J. Percutaneous irreversible electroporation (IRE) in the management of pancreatic cancer. J Vasc Interv Radiol 2014; 25 (3) S35
  • 20 Meijerink M. The PANFIRE study. Available at: https://clinicaltrials.gov/ct2/show/NCT01939665 . Accessed July 2015